A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

NCT07571824 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Participants

Interventions

DRUG: Selegiline TDS 6 mg/24 hours
DRUG: EMSAM® TDS 6 mg/24 hours

Sponsor

Corium Innovations, Inc.